Radionuclide therapy in oncology: The dawning of its concomitant use with other modalities?

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 31, Issue 7, 2004, Pages 929-931

  Valdés Olmos, Renato A ^a   Hoefnagel, Cornelis A ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; BIOTIN; BIOTIN Y 90; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETIDRONIC ACID RE 186; GEMCITABINE; IBRITUMOMAB TIUXETAN; LEXIDRONAM SAMARIUM SM 153; PREDNISONE; RADIOPHARMACEUTICAL AGENT; RITUXIMAB; STRONTIUM 89; TOPOTECAN; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; VINCRISTINE; YTTRIUM 90;

BONE METASTASIS; BONE PAIN; CANCER ADJUVANT THERAPY; CANCER PALLIATIVE THERAPY; CLINICAL RESEARCH; CLINICAL TRIAL; EDITORIAL; HUMAN; LOW DRUG DOSE; LYMPHOMA; MONOTHERAPY; NEUROBLASTOMA; ONCOLOGY; RADIOIMMUNOTHERAPY; RADIOISOTOPE THERAPY;

COMBINED MODALITY THERAPY; DRUG THERAPY; HUMANS; NEOPLASMS; RADIATION ONCOLOGY; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIOPHARMACEUTICALS; RADIOTHERAPY;

EID: 3142770407     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (14)

1. Logothetis C, Tu S, Navone N. Targeting prostate cancer bone metastases. Cancer 2003; 97:785-788.
2. Tu SM, Millikan RE, Menigistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomized phase II trial. Lancet 2001; 357:336-341.
3. Pagliaro LC, Delpassand ES, Williams D, Millikan RE, Tu SM, Logothetis CJ. A phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases. Cancer 2003; 97:2988-2994.
4. 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med 2002; 43:79-86.
5. Smeland S, Erikstein B, Aas M, et al. Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: results of a double-blind randomized study. Int J Radiat Oncol Biol Phys 2003; 56:1397-1404.
6. Horning SJ. Future directions in radioimmunotherapy for B-cell lymphoma. Semin Oncol 2003; 30 (Suppl 17):29-34.
7. Press OW, Unger JM, Braziel RM, et al. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood 2003; 102:1606-1612.
8. 131I-MIBG as a first line treatment in advanced neuroblastoma. Q J Nucl Med 1995 (Suppl 1):61-64.
9. Van Noesel MM, de Kraker J, Tygat GA, Hoefnagel CA, Caron HN. MIBG and topotecan combined induction therapy for high risk neuroblastomas: a phase I/II pilot study. Med Pediatr Oncol 2002; 39:257.
10. Mastrangelo S, Tornesello A, Diociaiuti L, et al. Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy. Br J Cancer 2001; 84:460-464.
11. Yanik GA, Levine JE, Matthay KK, et al. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol 2002; 20:2142-2149.
12. Grana C, Chinol M, Robertson C, et al. Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study. Br J Cancer 2002; 86:207-212.
13. McEwan AJB. Radioisotope therapy and clinical trial design: the need for consensus and innovation. J Nucl Med 2002; 43:87-88.
14. Hoefnagel CA, Clarke SEM, Fischer M, et al. Radionuclide practice and facilities in Europe. Eur J Nucl Med 1999; 26:277-282.